marimastat has been researched along with Arthritis, Degenerative in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baldus, JE; Carroll, JN; Caspers, N; Collins, B; Collins, J; Fletcher, TR; Grapperhaus, M; Hamper, BC; Hanau, CE; Hitchcock, J; Kleine, HP; Massa, M; McDonald, J; Messing, DM; Munie, GE; Palmquist, KE; Portolan, S; Rogers, MD; Ruminski, PG; Schmidt, M; Schnute, ME; Scholten, JA; Shieh, HS; Strohbach, J; Sunyer, T; Whiteley, LO | 1 |
1 other study(ies) available for marimastat and Arthritis, Degenerative
| Article | Year |
|---|---|
Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treat
Topics: Animals; Cartilage, Articular; Collagenases; Dogs; Drug Design; Humans; Kidney; Macaca fascicularis; Male; Matrix Metalloproteinase 13; Matrix Metalloproteinase Inhibitors; Models, Molecular; Organic Anion Transporters, Sodium-Independent; Osteoarthritis; Protein Binding; Pyrimidines; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship; Tetrazoles | 2016 |